To assess if preradiation and early follow-up measurements of relative regional cerebral blood flow (rrCBF) can predict treatment outcome in patients with cerebral metastases and to evaluate rrCBF changes in tumor and normal tissue after stereotactic radiosurgery using arterial spin-labeling (ASL) and first-pass dynamic susceptibility-weighted contrast-enhanced (DSC) perfusion MRI. Methods: In 25 patients with a total of 28 brain metastases, DSC MRI and ASL perfusion MRI using the Q2TIPS sequence were performed with a 1.5-T unit. Measurements were performed prior to and at 6 weeks, 12 weeks, and 24 weeks after stereotactic radiosurgery. Follow-up examinations were completely available in 25 patients for Q2TIPS and 17 patients with 18 metastases for DSC MRI. The rrCBF of the metastases and the normal brain tissue was determined by a region-of-interest analysis. rrCBF values were correlated with the treatment outcome that was classified according to tumor volume changes at 6 months. Results: The alteration of the rrCBF at the 6-week follow-up was highly predictive for treatment outcome. A decrease of the rrCBF value predicted tumor response correctly in all metastases for Q2TIPS and in 13 of 16 metastases for DSC MRI. The pretherapeutic rrCBF was not able to predict treatment outcome. The rrCBF values in normal brain tissue affected by radiation doses less than 0.5 Gy remained unchanged after therapy. Conclusion: These preliminary results suggest that ASL and DSC MRI techniques determining rrCBF changes in brain metastases after stereotactic radiosurgery allow the prediction of treatment outcome.
difficult to visualize using conventional MRI. Radiosurgery often has delayed effects on normal tissue, causing a transient contrast enhancement after therapy. In patients with irradiated brain metastases, it is often unclear whether a previously 17, 18 reported increase of contrast material uptake during follow-up on conventional, contrast-enhanced MR images is transient due to the radiation itself or is progressive due to tumor progression. To reach a specific diagnosis and a justifiable treatment decision, additional diagnostic information is necessary. 18 Previous MRI studies have shown that pathophysiological information can be obtained in patients with cerebral tumors using functional imaging methods, such as measuring tumor perfusion using the first-pass dynamic susceptibilityweighted contrast-enhanced (DSC) MRI. 16, 19 DSC echo-planar imaging (EPI) MRI has become a well-established method to determine relative regional cerebral blood flow (rrCBF) in normal and pathologic brain tissue. 19 Whenever application of contrast agents is needed for other functional imaging techniques, eg, for T1-weighted contrast-enhanced dynamic or pharmacokinetic MRI that is based on a pharmacokinetic two-compartment model and has been used successfully for assessing meningioma and malignant glioma response to stereotactic radiotherapy, 16, 20, 21 the ability to measure perfusion without using a contrast agent would be valuable.
MRI-based arterial spin-labeling techniques (ASL) are capable of measuring rrCBF without using extrinsic contrast agents by labeling spins of flowing arterial blood. They have been successfully used to measure rrCBF noninvasively in various pathologic conditions such as epilepsy, stroke, Alzheimer's disease, and brain tumors. 19, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Until now, several pulsed ASL schemes have been proposed. 28 In this work, the second version of quantitative imaging of perfusion by using a single subtraction with addition of thin-section periodic saturation after inversion and a time delay (Q2TIPS) sequence was investigated. 32 This approach for pulsed ASL, based on the flow-sensitive alternating inversion recovery (FAIR) labeling scheme, 23 is capable of multislice imaging like DSC EPI MRI.
The aim of our study was to assess whether preradiation rrCBF measurements and determination of early follow-up rrCBF would be able to predict treatment outcome in patients with cerebral metastases and to evaluate changes of rrCBF in metastases and normal brain tissue after stereotactic radiosurgery using arterial spin-labeling and DSC EPI perfusion MRI.
MATERIALS AND METHODS

Patients and Radiotherapy Treatment
The clinical trial was performed as an intraindividual follow-up study after stereotactic radiosurgery of brain metastases. The study population comprised 25 patients with 28 known metastatic brain lesions (11 female, 14 male; median age 57 years, range 25 to 73 years). The metastases derived from bronchiogenic tumors in 12 patients, breast carcinoma in 4 patients, melanoma, renal cell carcinoma, and colon carcinoma in 2 patients each, and testicular carcinoma, stomach cancer, and urinary bladder carcinoma in 1 patient each. All patients were referred for MRI of the brain for imagebased radiotherapy planning. Perfusion MRI and tumor volume measurements were performed before, 6 weeks, 12 weeks, and 24 weeks after stereotactic radiosurgery of brain metastases. Twenty-eight metastases were irradiated and examined by perfusion MRI. Stereotactic radiosurgery of the brain metastases consisted of a single dose of a median of 18 Gy (range, 16 -20 Gy) referred to the 80% isodose. In our department, 1 to 3 brain metastases per patient were treated by stereotactic radiosurgery. 7 All treatment sessions were carried out on a linear accelerator (Primus, Siemens Inc., Erlangen, Germany). The study was approved by the institutional review board and was conducted according to the declaration of Helsinki. Written informed consent was obtained from all patients after the nature of the examination had been fully explained to them.
MRI Protocol
Examinations were performed prospectively with a 1.5-T MR unit (Magnetom Vision Plus, Siemens Inc., Erlangen, Germany) using the standard circular-polarized head coil. An axial T2-weighted turbo-spin-echo (TSE) sequence (repetition time ͓TR͔/echo time ͓TE͔ ϭ 3840 milliseconds/99 milliseconds) was used to position the Q2TIPS ASL perfusion sequence. The Q2TIPS sequence is based on the "Quantitative Imaging of Perfusion using Single Subtraction II" sequence (QUIPSSII). 33, 34 Sequence parameters of the Q2TIPS were as follows: TE ϭ 30.5 milliseconds, measurement interval (TR) ϭ 2500 milliseconds, TI ϭ 1200 milliseconds (inversion time), TI2 ϭ 200 milliseconds (time delay between saturation pulse and image acquisition), 128 ϫ 128 matrix, 240-mm field of view (FOV), slice thickness 8 mm, 5 slices obtained in 1 acquisition, total acquisition time 4 minutes 42 seconds, 50 averages. MR examinations for treatment planning of the brain metastases were performed separately with an individual precision Scotch-Cast (Laboratories 3M Sánte, Cergy Pontoise, France) mask system, immediately after perfusion imaging.
Before administering contrast medium, the diagnostic MRI protocol included an axial fast low-angle shot (FLASH) 3D-sequence (TR/TE ϭ 20 milliseconds/6.5 milliseconds). A loading dose of 0.1 mmol/kg body weight of gadopentetate (Magnevist, Schering, Berlin, Germany) was administered to diminish T1-shortening effects due to blood-brain barrier disruption within the brain metastases according to the recommendations of Aronen et al 35 and Warmuth et al. 31 After-wards, 50 T2*-weighted gradient-echo images were acquired before, during, and after intravenous bolus injection of 0.2 mmol/kg body weight of gadopentetate using a multislice first-pass DSC free induction decay echo-planar imaging (FID-EPI) sequence. A double dose of contrast medium was applied as recommended previously. 19, 31, 36 The infusion rate was 5 mL/s by using a power injector and started with the second of the 50 DSC measurements. Sequence parameters were: measurement interval (TR) ϭ 1000 milliseconds, TE ϭ 54 milliseconds, slice thickness 8 mm, 5 slices obtained in 1 acquisition, 128 ϫ 128 matrix, 50 measurements, 240-mm FOV. After the DSC EPI sequence, postcontrast axial fluidattenuated inversion recovery (FLAIR) (TR/TE ϭ 9000 milliseconds/105 milliseconds), axial FLASH 3D (TR/TE ϭ 20 milliseconds/6.5 milliseconds), and coronal magnetization transfer-T1-weighted spin-echo (SE) (TR/TE ϭ 610 milliseconds/20 milliseconds) sequences were performed. Consequently, a cumulative triple dose of contrast medium was used to improve detection of brain metastases according to the recommendations of Runge et al. 37 Depending on the physical condition and compliance of the patients, mask fixation was omitted during follow-up. Imaging protocol then included axial T2-weighted TSE, Q2TIPS, T1-weighted SE (TR/TE ϭ 600 milliseconds/20 milliseconds), DSC FID-EPI MRI, contrast-enhanced FLAIR, contrast-enhanced magnetization transfer-T1-weighted SE (TR/TE ϭ 600 milliseconds/20 milliseconds), and contrast-enhanced coronal magnetization transfer-T1-weighted SE sequences.
Data Analysis
MR images were assessed both quantitatively and qualitatively. The quantitative analysis of perfusion data involved determination of rrCBF values measured by placing representative regions of interest (ROIs) on the tumor and the brain tissue of the contralateral hemisphere that appeared normal on conventional MR images and that was affected by radiation doses less than 0.5 Gy. 38 After such low doses of irradiation, in a recent study no rrCBF changes have been observed in healthy brain tissue. 39 Six ROIs of 6 pixels in size each were placed both on gray and white matter of the contralateral hemisphere to average distribution of flow values in the different regions of the brain. 19 In follow-up examinations, an effort was made to achieve identical positioning of the ROIs by using anatomic landmarks as orientation. Peritumoral edema was avoided. The ROI placed on the metastasis included all enhancing tissue and avoiding nonenhancing, possibly necrotic areas, and had a size of at least 15 pixels. All ROIs were defined in consensus of 2 radiologists and 1 radiation oncologist. rrCBF maps of the DSC EPI MRI were calculated using the singular value decomposition as described by Ostergaard et al. 40 A fixed threshold of 15% was used, i.e., the lowest 15% singular values were discarded. rrCBF values were calculated using the principle of the indicator dilution theory, which postulates that the increase in blood susceptibility induced by a contrast agent is proportional to its concentration in the blood pool. 41, 42 The arterial input function (AIF) was determined by placing a ROI near the middle cerebral artery as recommended by Scholdei et al 43 and Sorensen and Reimer. 19 For each measurement, rrCBF ratios of white to gray matter (WM/GM) and metastasis to gray matter (Met/GM) were calculated as major parameter of interest because of the following considerations. Accurate quantification of CBF by using ASL sequences depends on arterial transit times to the voxels, local relaxation times of tissue and blood, and the equilibrium magnetization of the blood. 31 Systematic errors of blood flow quantification by ASL result from the assumption of a constant T1 relaxation time of arterial blood irrespective of vessel size and blood oxygenation. 31 Therefore, although controversially discussed in the literature, 27 ,28,31 our conservative opinion according to Barbier et al 28 is that absolute blood flow quantification by ASL in brain lesions is complicated, because the prerequisites mentioned above cannot exactly be determined. 28 Taking these considerations into account, CBF values in Met, GM, and WM are proportional rather than equivalent to the actual regional CBF values.
Regarding DSC EPI MRI, our conservative opinion in accordance with Sorensen and Reimer 19 on our approach placing the AIF in proximity to the middle cerebral artery is that the measured CBF values are relative rather than absolute. Furthermore, in brain lesions with disrupted blood-brain barrier, assumptions of negligible recirculation and contrast agent leakage by the indicator dilution theory are violated. 44 -46 Therefore, in our study, using a reference to an internal standard by calculating rrCBF values normalized to the contralateral hemisphere seems to be the best way of comparing the different perfusion techniques and patients, although ratios incorporate possible measurement errors of both values. In clinical practice, rrCBF and relative regional cerebral blood volume (rrCBV) measurements have been shown to correlate with tumor vascularity and have been used successfully for differentiating brain tumors 31, 35, 44, 47 and for discriminating between therapy-related effects from tumor recurrence in follow-up studies. 48, 49 As cerebral metastases are mainly situated cortically 1 and CBF values measured by ASL probably best match actual flow in gray matter, 31 we chose the rrCBF ratio of Met/GM as primary parameter of interest. Cha et al 44 also recommended the reference ROI to be placed on the contralateral gray matter, when the lesion is situated predominantly cortically. Although of limited physiological significance, the rrCBF ratio of WM/GM in normal brain tissue was chosen as parameter of interest in accordance with a recent study using DSC MRI and 99m Tc-hexamethylpropyleneamine oxime single photon emission CT (99mTc-HM-PAO SPECT). 50 In the evaluation of intracranial mass le- sions, until now, CBV has been mostly measured. 44 Because the clinically widespread perfusion-related parameter rrCBV could not be measured by using the Q2TIPS ASL technique, only rrCBF could be reliably measured by both perfusion sequences used in this study. Consequently, other parameters were not calculated using DSC EPI MRI.
The qualitative analysis involved evaluation of conventional MRI data to categorize the patient's tumor response. The qualitative categorization of tumor response was done by consensus of 2 radiologists and 2 radiation oncologists. Tumor response to radiation therapy was classified on the basis of the 6-month follow-up findings as the following: 1: tumor remission ϭ tumor volume decrease of more than 25%; 2: stable disease ϭ tumor volume decrease of less than 25% or a tumor volume increase of less than 25%; and 3: tumor progression ϭ tumor volume increase of more than 25%. The pretherapy tumor volume was considered the reference volume. Volumes of metastases () were estimated on contrastenhanced T1-weighted images, assuming an ellipsoid shape: ϭ 4/3 * * a * b * c with a, b, and c being half the diameter in 3 orthogonal directions.
Statistical Analysis
The tumor response was cross-correlated with the rrCBF Met/GM changes of the metastasis determined by both Q2TIPS and DSC EPI MRI prior to and at 6 weeks after therapy and evaluated by a 2 test. The final tumor response was defined on the basis of the tumor volume categorization at the follow-up of 6 months.
Sensitivity, specificity, and predictive values for treatment outcome were calculated at the 6-week follow-up for the rrCBF Met/GM and tumor volume based on the tumor outcome using a 2 test (patients with stable disease and remission were combined in a "responder" group). At this time-point, a reduction of the rrCBF Met/GM or a tumor volume decrease was categorized as predicting a tumor remission. An increase of the rrCBF Met/GM or the tumor volume was categorized as predicting a tumor progression. Because of the limited number of patients, a formal receiver operating characteristic (ROC) analysis to obtain a possibly optimal threshold value for prediction of tumor response was not performed. rrCBF Met/GM ratios of the lesions measured prior to therapy and at the 6-week follow-up were tested for a difference with the nonparametric Wilcoxon matched pairs signed rank test. rrCBF Met/GM values prior to therapy were compared in the different outcome groups using a Kruskal-Wallis test.
The time independence of the normal tissue rrCBF was investigated by evaluating differences in the median WM/GM rrCBF ratios of both perfusion imaging methods using Duncan's multiple range test for analysis of variance (ANOVA). For all statistical testing, a P value less than 0.05 was considered to indicate a significant difference.
RESULTS
The patient population, including treatment doses, initial metastases volumes and localization, primary tumors, and initial rrCBF Met/GM values, is summarized in Table 1 according to tumor response. Thirteen patients (13 metastases) demonstrated tumor remission, 10 patients (11 metastases) stable disease, and 3 patients (4 metastases) tumor progression at the 6-month follow-up examination (Figs. 1  and 2 ). In 1 patient with 3 irradiated metastases, 2 showed progression, while 1 showed remission (Fig. 2) . 
Tumor rrCBF
The time course of tumor rrCBF obtained by Q2TIPS and DSC EPI MRI is summarized in Tables 2 and 3 , respectively. There was no difference in initial rrCBF Met/GM values between tumors that subsequently responded to therapy (responders) and tumors that did not respond (nonresponders) (Q2TIPS: P ϭ 0.82; DSC EPI MRI: P ϭ 0.83).
In the responder group (stable or decreasing tumor volume; n ϭ 23, 24 metastases), the early drop of rrCBF values at the 6-week follow-up measurement was predictive of tumor response. Using the Q2TIPS sequence, in all patients with tumor remission, a decrease of rrCBF Met/GM at the 6-week follow-up was observed (median decrease of 0.44, P ϭ 0.001). In all patients with stable disease, a decrease of rrCBF Met/GM at the 6-week follow-up was observed (median decrease of 0.16, P ϭ 0.002). In the nonresponder group (n ϭ 3, 4 metastases), an increase of rrCBF Met/GM at the 6-week follow-up was observed in all patients (median increase of 0.05, P ϭ 0.25).
Using DSC EPI MRI, interpretable rrCBF perfusion maps during all follow-up examinations could only be performed in 17 patients (18 metastases, table 1), because placement of a large intravenous catheter necessary to rapidly intravenously inject a narrow bolus of contrast agent was not always possible in the examined tumor patients. In the responder group (n ϭ 16, 16 metastases), a substantial decrease of rrCBF Met/GM values at the 6-week follow-up could be observed. In 8 of 9 patients with tumor remission, a decrease of rrCBF Met/GM at the 6-week control time point was observed (median decrease of 0.49, P ϭ 0.06). In 5 of 7 patients with stable disease, a decrease of rrCBF Met/GM at the 6-week follow-up was observed (median decrease of 0.15, P ϭ 0.38). In the nonresponder group (n ϭ 1, 2 metastases), an increase of rrCBF Met/GM at the 6-week follow-up was observed in both metastases (median increase of 0.39, P ϭ 0.5).
In 1 patient, who ultimately had a tumor remission, a decrease of rrCBF Met/GM ratio at the 6-week follow-up was observed despite a transient tumor volume increase. A transient decrease in tumor volume at the 6-week follow-up was observed in 1 patient, who ultimately had a tumor progression. In this patient, at 6 weeks post-therapy, increase of the rrCBF Met/GM ratio predicted nonresponse to therapy. In our patient population, sensitivity of tumor rrCBF Met/GM obtained by Q2TIPS for an early prediction of the outcome to radiotherapeutic treatment was significantly better than tumor volume (P ϭ 0.036, Table 4 ). At the 6-week follow-up time point, specificity and positive predictive values of the rrCBF Met/GM measured by Q2TIPS and DSC EPI MRI were higher than those of the tumor volume (Table 4) .
rrCBF of Normal Brain Tissue
rrCBF ratios of unaffected, healthy brain tissue of the patients obtained by Q2TIPS and DSC EPI MRI remained unchanged after stereotactic radiosurgery of brain metastases. Duncan's test for ANOVA showed that WM/GM rrCBF ratios obtained by both perfusion imaging techniques were not significantly different on follow-up (P Ͼ 0.05, Table 5 ).
DISCUSSION
The preliminary results of our study suggest that the analysis of rrCBF Met/GM ratios before radiosurgery and at early follow-up after stereotactic radiosurgery can predict tumor response in patients with brain metastases. Tumor is inferior to the DSC EPI MR images, but the hyperperfused rim of the metastasis in the left frontal lobe is clearly visible. B: Sixty-seven-year-old female patient with brain metastases from renal cell carcinoma. First column shows T2-weighted TSE MR images, second column (b, h) contrast-enhanced T1-weighted gradient-echo and (e) spin-echo MR images. (c, f, i) Perfusion maps obtained by the Q2TIPS sequence. The top row shows MR images before stereotactic radiosurgery (a-c), the middle row 6 weeks after stereotactic radiosurgery (d-f), and the bottom row 24 weeks after stereotactic radiosurgery (g-i). Before stereotactic radiosurgery, the contrast agent-enhancing metastasis in the left frontal lobe showed hyperperfusion with rrCBF Met/GM ratio of 5.9. Six weeks after radiosurgery, the metastasis showed a reduction in size (e). Corresponding rrCBF Met/GM ratio dropped to 2.2 (f). Twenty-four weeks after irradiation, the tumor size further decreased (h), and the rrCBF Met/GM ratio decreased to 0.4 (i). Note the newly developed hyperperfused metastasis in the right frontal lobe with an rrCBF Met/GM ratio of 2.6 (h-i). Hypoperfusion of the left frontoparietal area is most probably caused by edema. The images b and h are acquired in mask-fixation. Therefore they are in a slightly different orientation. response to stereotactic radiosurgery may be evidenced before tumor volume changes can be observed, yielding a therapeutic window to broaden treatment options and to improve treatment outcome. The follow-up interval using morphologic MRI was at least 6 months. In metastases, the rrCBF Met/GM values depend on the vascularization of the primary tumor, which may explain the spread of the values in this heterogeneous group of patients. Particularly, metastases from renal cell carcinoma had high rrCBF Met/GM ratios in accordance with their known increased vascularity. 51 Within a single metastasis, blood flow is reported to be homogeneous within the enhancing area. 2 In the present study, differences between treatment responders and nonresponders could not be distinguished on the basis of initial tumor rrCBF Met/GM values. Whereas this may be related to the pronounced spread of initial values, determination of relative regional CBF values, and the limited number of patients, it also may be argued that the initial vascularization of the pathologic tissue has no influence on the radiotherapeutic effect, as suggested previously in a study using positron emission tomography (PET). 52 However, we found that an early decline of CBF within the metastasesnormalized to that in gray matter-reliably predicted the ultimate treatment response, as determined by the lesion size after 6 months of follow-up. This was independent of any initial change in tumor size. A limitation of the reported study is the limited number of patients. Although there were only 25 patients completely assessable, all patients had a standardized imaging protocol and a follow-up MRI after at least 6 months.
Because of the limited number of patients, the good performance of the Q2TIPS technique in our preliminary study has to be carefully interpreted. Particularly the low number of nonresponder metastases (14%), although expected because of the good local control rate of stereotactic radiosurgery, diminishes the accuracy of the statistical evaluation. Complicating this is the fact that 2 of the 4 nonresponder metastases (50%) are melanoma metastases, while only 2 of the 24 stable or regressing metastases derive from a melanoma (8%). To obtain the actual sensitivity and specificity of ASL and DSC EPI MRI, in a nonpreliminary study, probably 150 metastases have to be examined to gain a Note: Regarding sensitivity, the 95% confidence interval was 78% to 100% for Q2TIPS, 44% to 98% for DSC EPI MRI, and 58% to 95% for the tumor volume. sufficient number of nonresponders. In our opinion, the actual performance of Q2TIPS ASL MRI therefore might be similar to DSC EPI MRI. Both ASL and the used DSC EPI sequence, despite T1-shortening correction by preinjection, may systematically underestimate blood flow in brain lesions with high tumor blood flow and disrupted blood-brain barrier, as present in some metastases and high-grade gliomas. 31, 45, 46 Improvement of DSC MRI sequences using a double-echo technique 53 that make optimized T-shortening correction algorithms possible may increase the accuracy of CBF values in these tumors. Nevertheless, rrCBF values, which were the focus of our investigation, measured by DSC EPI MRI are less affected by a disrupted blood-brain barrier than rrCBV values. 31 A close linear correlation between DSC EPI and Q2TIPS ASL MRI in determining relative tumor blood flow (rTBF) has been described in a recent study on 29 patients with gliomas and 7 patients with brain metastases. High-and low-grade gliomas could be distinguished at the same level of significance with both methods by determining rTBF, showing significantly higher rTBF in untreated high-grade gliomas than in untreated low-grade gliomas. 31 In our study, radiation-induced perfusion changes in brain metastases were found using both Q2TIPS ASL and DSC EPI MRI. Although our data on the rrCBF Met/GM values obtained by DSC EPI MRI show the same tendency as Q2TIPS, they could not be statistically substantiated, probably due to fewer patients who could be evaluated.
A single high-dose treatment as in radiosurgery directly affects vessels of tumors and normal brain parenchyma. Radiosurgery induces endothelial damage, leading to proliferation of the intimal layer and smooth-muscle cells of the vessel wall. Reduction in microvessel flow occurs. Fibrinoid swollen, thickened, and necrotic vessel walls have been observed, causing progressive stenosis and even complete obliteration, even in large vessels, both in normal brain and tumor tissue. 54 -56 Reduction of tumor vascularity has been shown to be concordant with response to therapy, whereas an increase in vascularity accompanied tumor progression. 55 The findings of the present study measuring rrCBF as surrogate parameter of perfusion are in agreement with a recent study on 18 patients with irradiated cerebral metastases determining regional CBV by DSC MRI using a simultaneous dual FLASH sequence. 57 The authors showed that by determining changes of tumor blood volume, an early prediction of treatment outcome was possible. However, using this FLASH sequence, 41 only 1 slice was available for measuring CBV, so that in case of more than 1 metastasis treated by stereotactic radiosurgery, not all lesions could be evaluated. In our department, 1 to 3 brain metastases per patient are treated by stereotactic radiosurgery. 7 We showed in our study that by using multislice techniques and by measuring rrCBF, a prediction of treatment outcome of all brain metastases per patient treated by stereotactic radiosurgery was possible as well.
After stereotactic radiosurgery, no significant temporal variations of rrCBF obtained by both sequences in normal brain tissue of the contralateral hemisphere were found, although ROI analysis may be limited due to partial volume effects and difficulties in the identical positioning of the ROIs on follow-up examinations. Our findings are in accordance with a recent study on 62 patients using MRI for measurement of perfusion. 39 However, in a recent study on 13 patients, a reduction of regional CBF at 2 weeks and 3 months after stereotactic radiosurgery in out-of-field areas (Ͻ5 Gy) was observed by 99m Tc-HMPAO scintigraphy. 58 High precision stereotactic radiosurgery is used to deliver high doses of radiation to small intracranial tumors, while the dose to surrounding normal brain tissue is minimized due to the steep radiation dosage decline at the border of the target volume. 5, 8 In our study, the normal brain parenchyma examined was only affected by radiation doses less than 0.5 Gy, 38 which might explain the conflicting results.
The Q2TIPS sequence generally yielded lower WM/GM rrCBF ratios than DSC EPI MRI in accordance with previous reports (DSC MRI: WM/GM ratio of 0. 48, 41 Q2TIPS: WM/GM ratio of 0.33 32 ). The observed WM signal obtained by Q2TIPS was only slightly higher than background noise, in agreement with previous findings. 34 The main disadvantage of ASL techniques is that the signal-tonoise ratio (SNR) is lower than with DSC EPI MRI, because only up to 4% of the voxel volumes consist of capillary volume filled with potentially labeled blood in gray matter. Hence, a longer acquisition time is needed for the ASL sequences to create images with a sufficient SNR (about 5 minutes compared with 1 minute of the first-pass DSC EPI MRI). A SNR improvement is expected from the use of higher field strengths like 3 T. Possibly, with the increasing number of high-field MR scanners, these perfusion techniques will be used more often. Moreover, venous blood causes artifacts in the sagittal sinus and other large intracerebral veins using ASL imaging. 34 Furthermore, brain metastases and postirradiation reaction are able to cause edema that may cause a prolonged transit time in and near the tumor, resulting in a slower blood flow that decreases the SNR in ASL imaging unless correction algorithms 25, 26 are used. Advantages of the Q2TIPS ASL technique are the immediate availability of the perfusion-weighted difference image after the acquisition without any manual postprocessing, no power injector has to be prepared, and no large intravenous catheter has to be placed. Advantages of contrast medium-based techniques, besides a far better SNR, are the possibility of acquiring a larger total number of sections and more sections in a shorter time than with ASL imaging. Furthermore, other perfusion-related parameters such as CBV and MTT can be calculated using DSC MRI.
CONCLUSIONS
The preliminary results of our study suggest that both dynamic susceptibility-weighted contrast-enhanced MRI and arterial-spin labeling perfusion MRI determining rrCBF prior to and at 6 weeks after stereotactic radiosurgery of brain metastases are suitable methods for assessing local tumor control. With the methods used, a better prediction of treatment outcome in patients with brain metastases is possible. Temporal changes in tumor microcirculation after stereotactic radiosurgery can be observed by both methods.
